- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01494974
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
INTRODUCTION
The drainage implants have become an important alternative in the treatment of pediatric glaucoma refractory to angular and filtration surgery or medical therapy (1). Such implants drain the aqueous humor from the anterior chamber of the eye to a plate positioned above the sclera, between the rectus muscles. The aqueous humor goes through the pseudocyst that forms around the plate by passive diffusion and is drained by the venous capillaries and lymphatic system.
The Ahmed drainage implant (New World Medical, Inc., Rancho Cucamonga, CA, USA) is a device with flow restrictors, which decreases the incidence of postoperative complications such as hypotony (2-3). It is made of silicone and comes in two sizes. The FP7 model has a surface of 184 mm2, 13mm wide and 16mm long. The FP8 model presents 96mm2 surface, 9.6 mm wide and 10mm long.
Studies in animals and adult humans suggest that the surface area of the implant plate is directly related to the amount of aqueous fluid drained through the same (4-7). In contrast, a very large implant can result in the extrusion of the same, uncontrolled intraocular pressure, corneal injury by endothelial touch, patient discomfort and ocular motility problems. The use of pediatric size implants in small eyes can avoid such complications. A high rate (34.8%) of anterior plate of the tubes in children under 2 years of age has been reported (8-9). On the other hand, the use of pediatric implante may affect the control of intraocular pressure (IOP) due to reduced drainage area (10), especially in eyes with increasing axial diameter, a result of increased eye pressure that happens in children with glaucoma. However, there is no study in the literature comparing different sizes of drainage implants in pediatric patients.
A study to compare the success rates and complications between FP7 and FP8 models is essential in order to standardize a conduct in choosing the type of implant. Currently, the choice of the drainage implant model to be used in every child lies on the free choice and personal preference of the surgeon. There is no standard procedure, based on scientific evidence for this choice.
OBJECTIVES
Compare the success rates and complications of two models of Ahmed drainage implant (FP7 and FP8) in patients with pediatric glaucoma.
MATERIALS AND METHODS
This clinical trial is a prospective, randomized, masked to the evaluator to be held at the Department of Ophthalmology, Federal University of Sao Paulo.
Will be included children between 0 and 10 years of age with glaucoma and surgical indication for glaucoma drainage implant. Surgical indication for implantation of Ahmed drainage occurs in some situations: 1) children with primary congenital glaucoma that undergone angular surgery (goniotomy and / or trabeculotomy) who did not respond satisfactorily to surgery, 2) children with glaucoma secondary to aphakia who have the primary indication for implantation of Ahmed drainage, 3) children with glaucoma secondary to other eye disorders where medical treatment is not satisfactory.
A term of consent will be obtained from parents or legal guardians of the child, in which all the risks inherent to the surgical procedure will be clarified. Such risks are proper to antiglaucomatous surgery are:
- Early: hypotony, hyphema, tube endothelial touch, choroidal detachment, leakage of aqueous, vitreous hemorrhage, retinal detachment, loss of light perception
- late: uncontrolled intraocular pressure, persistent hypotony, scleral patch resorption, extrusion of the tube, retinal detachment, loss of light perception (11-18).
Considering that the selected patient has already the surgical indication for Ahmed drainage implant, the inclusion of this child in the study does not bring additional risks or discomforts to the same.
The model of the drainage implant will be chosen through allocation from a computer-generated random table.
Children enrolled in the study will be divided into two groups (one group will receive the model FP7 and another group will receive the model FP8) with the number of 20 participants in each group, totaling 40 children.
The surgeries will be performed by experienced surgeons from Glaucoma Sector from Department of Ophthalmology, Federal University of Sao Paulo.
The plate of the Ahmed drainage implant will be placed in one of the quadrants selected from the extraocular muscles between 8 and 10 mm away from the corneal limbus. The tube will have its distal portion inserted 2-3mm into the anterior chamber of the eye in the iris plane. The exposed portion of the tube is covered with donor sclera.
The children included in the study will be examined before surgery, which will be measured your visual acuity, biomicroscopy, IOP, Retinography and axial length of the eye. Immediately after surgery, with a compass we will measure the distance between the plate of drainage implant and corneal limbus.
Children will be examined again after 6 months and 1 year of surgery. We will perform the measurement of visual acuity, biomicroscopy, IOP, Retinography, axial length and measurement of the distance from the plate of the implant and corneal limbus. Post-operative examinations will be performed under narcosis, in hospitals (when it is impossible to take measures in an outpatient setting due to lack of cooperation of the child), by a doctor from congenital glaucoma sector who were not involved in the surgical procedure. The examination under narcosis involves risk to the child, which include cough, nausea, vomiting, laryngospasm, bronchospasm, apnea, bradycardia, tachycardia, hypertension, anxiety (19-21).
Two types of outcome will be considered in this study. The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the dish drain implant is positioned at a distance <8 mm from the corneal limbus, we have a failure.
As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative. We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.
For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Camila F Netto, MD
- Phone Number: +55-1199177717
- Email: milanetto@gmail.com
Study Locations
-
-
-
São Paulo, Brazil, 04023-062
- Recruiting
- Federal University of São Paulo - Ophthalmology Department
-
Contact:
- Camila F Netto, MD
- Phone Number: +55-11-99177717
- Email: milanetto@gmail.com
-
Principal Investigator:
- Camila F Netto, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnostic of Pediatric Glaucoma with indication of Ahmed Glaucoma Valve implantation
- Age from 0 to 10 years old
Exclusion Criteria:
- Children older then 10 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: FP7 implant
|
Ahmed Glaucoma Valve model FP7
|
Active Comparator: FP8 implant
|
Ahmed Glaucoma Valve model FP8
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Position of the drainage implant plate
Time Frame: After 1 year of surgery
|
The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful.
If the plate is positioned at a distance <8 mm from the corneal limbus, we have a failure.
|
After 1 year of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
As a secondary outcome, we evaluate the variation in IOP preoperative and postoperative.
Time Frame: After 1 year of surgery
|
We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined. For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception. |
After 1 year of surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Camila F Netto, MD, Assistant Doctor at Ophthalmology Department
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP 0236/11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Glaucoma
-
Mansoura UniversityNot yet recruiting
-
Johannes Gutenberg University MainzRecruitingIntraocular Pressure | Anesthesia | Glaucoma, Suspect | Pediatric GlaucomaGermany
-
Shahid Beheshti University of Medical SciencesCompletedPediatric Aphakic GlaucomaIran, Islamic Republic of
-
Alcon ResearchCompletedPediatric Glaucoma | Elevated IOP in Pediatric Patients | Ocular Hypertension in Pediatric Patients
-
Mansoura UniversityEnrolling by invitationPediatric GlaucomaEgypt
-
Sun Yat-sen UniversityActive, not recruitingCongenital Cataract | Glaucoma Secondary | Glaucoma Following Pediatric Cataract Surgery
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
Clinical Trials on FP7 Ahmed Glaucoma Drainage Implant
-
Peter Netland, MDNew World Medical, Inc.Completed
-
University of MiamiNational Eye Institute (NEI); Research to Prevent BlindnessCompleted
-
SOLX, Inc.SuspendedGlaucoma | Glaucoma, Open AngleUnited States, Israel, Canada, India, Poland
-
Robert FeldmanTerminated
-
Centre hospitalier de l'Université de Montréal...RecruitingGlaucoma | Corneal TransplantationCanada
-
Ain Shams UniversityCompletedGlaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Secondary
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Menoufia UniversityMansoura UniversityCompleted
-
Credit Valley EyeCareGlaucoma Research Society of CanadaCompletedGlaucomaUnited States, Canada, Chile
-
Tissue Tech Inc.Columbia University; National Eye Institute (NEI); Bascom Palmer Eye Institute; The New York Eye & Ear InfirmaryCompleted